Nektar Therapeutics · NASDAQ:NKTR
Zalevsky Jonathan sold 186 Nektar Therapeutics shares (Form 4)
Traded Aug 18, 2026 · Filed Aug 20, 2026
On Aug 18, 2026, Zalevsky Jonathan (Chief R&D Officer) sold 186 Nektar Therapeutics shares at US$71.98 for US$13,388, leaving 9,570 shares. Filed Aug 20, 2026 (Form 4).
- Sold
- 186 shares
- Price
- US$71.98
- Value
- US$13,388
- Holding after
- 9,570 shares
- Trading plan
- No
- Role
- Chief R&D Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | Common Stock | Sale | 186 | US$71.98 | 9,570 | Direct |
Source
Related
- Nektar Therapeutics
- Zalevsky Jonathan
- Nektar Therapeutics shareholders
- Form 4 · Zalevsky Jonathan · Jul 2, 2026
- Form 4 · Zalevsky Jonathan · Jun 17, 2026
- Form 4 · Zalevsky Jonathan · May 21, 2026
- Schedule 13G/A · Two Seas Capital LP · Sep 28, 2026
- Form 4 · Whitfield Roy A · Sep 25, 2026
- Form 4 · Greer R Scott · Sep 25, 2026
- Form 4 · Chess Robert · Sep 25, 2026
- Form 4 · Brainard Diana · Sep 25, 2026